Top Story

Artificial hybrid likely required for treating giant cell tumor of bone with zoledronic acid

January 29, 2015

In a recently published study, researchers determined that to effectively treat giant cell tumors of bone with zoledronic acid, a hybrid including artificial bone would be needed.

The researchers evaluated five patients with giant cell tumor of bone treated with zoledronic acid between 2008 and 2013 at a single institution. The tumors were either grade II or III on the Campanacci scale. Four patients received zoledronic acid with artificial bone, and one patient was administered the treatment without it. Surgically resected specimens were utilized to determine the patients’ histologic response.

FDA News

FDA expands approval of Imbruvica to treat Waldenström's macroglobulinemia

January 29, 2015
The FDA today announced the expanded approval of ibrutinib for the treatment of Waldenström’s macroglobulinemia, a rare form of non-Hodgkin’s lymphoma…
In the Journals

Biomarkers predicted severity of GVHD after allogenic HSCT

January 29, 2015
A prognostic score based on the concentration of biomarkers guided risk-adapted therapy at the onset of graft-versus-host disease following allogeneic hematopoietic stem…
Jae Cheol Lee, MD, PhD In the Journals

Pemetrexed benefited lung cancer patients with ALK mutations

January 29, 2015
Patients with lung adenocarcinoma who have anaplastic lymphoma kinase gene mutations derived greater benefit from pemetrexed-based therapy than those without the…
Srdan Verstovsek In the Journals

Ruxolitinib superior to standard therapy for polycythemia vera

January 28, 2015
Patients with polycythemia vera who were resistant to or intolerant of hydroxyurea therapy demonstrated better controlled hematocrit levels, reduced spleen volume and…
More News Headlines »
CME CNE
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video
Genome editing demonstrated wide application for blood disorders

Genome editing demonstrated wide application for blood disorders

January 4, 2015
SAN FRANCISCO — Ralph Green, MD, PhD, FRCPath, medical director of the UC Davis Health System Medical…
More »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
morganatic-roan
morganatic-roan